A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

Clinical trial NCT06947811 · RECRUITING

Trial details

NCT number: NCT06947811
Sponsor: Sun Yat-sen University
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

Start date: 2025-06-09
Primary completion: 2027-03-01
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.